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PURPOSE. To investigate the relationship between pulse wave velocity (PWV) and retinal
vessel density (VD) measured by optical coherence tomography angiography (OCTA) in
patients with normal-tension glaucoma (NTG).
METHODS. This retrospective study included 103 patients with NTG and 109 healthy
controls who underwent glaucoma examination and PWV measurements. Each group
was classified into two subgroups according to a brachial-ankle PWV of 1400 cm/s. NTG
was diagnosed when the maximum untreated intraocular pressure was < 21 mmHg on
three repeated measurements obtained at different times in the presence of glaucoma-
tous optic discs (neuroretinal rim thinning and excavation), peripapillary retinal nerve
fiber layer defects, and glaucomatous visual field defects. Healthy controls did not have
glaucomatous optic discs or visual field defects and exhibited normal retinal nerve fiber
layer thickness. The interval between glaucoma examination and PWV measurements
did not exceed six months. Univariate and multivariate logistic regression analyses were
performed to identify factors associated with high PWV.
RESULTS. PWV was higher in the NTG group than in the control group, while peripapillary
VD and macular VD (mVD) were lower (all P< 0.05). Stepwise logistic regression analysis
revealed that high PWV was significantly associated with age, mean arterial pressure
(MAP), and mVD in the NTG group. Meanwhile, high PWV was significantly associated
with age, MAP, and low-density lipoprotein cholesterol levels in healthy controls.
CONCLUSIONS. High PWV is associated with decreased mVD in NTG patients, suggesting
that systemic arterial stiffness might be involved in the pathogenesis of NTG.
Keywords: pulse wave velocity, optical coherence tomography angiography, vessel
density, normal-tension glaucoma
Glaucoma is characterized by progressive optic neuropa-thy with characteristic loss of optic nerve fibers and
retinal ganglion cells (RGCs).1 There are two principal theo-
ries for the pathogenesis of glaucoma—a mechanical theory
and a vascular theory.2 According to the mechanical theory,
intraocular pressure (IOP) causes mechanical stretching of
the lamina cribrosa and damage to RGC axons. The vascu-
lar theory states that insufficient blood supply due to either
increased IOP or other risk factors causes a reduction in
ocular blood flow.3–5 The vascular theory is particularly rele-
vant to normal-tension glaucoma (NTG) since glaucoma-
tous optic neuropathy often progresses in spite of low IOP
in NTG. Therefore, numerous studies have investigated the
relationship between vascular dysregulation and NTG.
Arterial stiffness, which refers to a loss of arterial elas-
ticity, reflects vascular aging. Pulse wave velocity (PWV) is
among the methods for representing systemic arterial stiff-
ness and is a useful marker for predicting future cardiovas-
cular events.6,7 PWV has been associated with eye diseases
such as diabetic retinopathy,8,9 retinal vein occlusion,10 and
age-related macular degeneration.11 Although several stud-
ies have investigated the relationship between PWV and
glaucoma, their results have been inconsistent.12–17 There-
fore, the role of PWV in glaucoma remains controversial.
The recent introduction of optical coherence tomography
angiography (OCTA) allows for the noninvasive measure-
ment of retinal vessel density (VD) in the peripapillary
and macular areas.18,19 Studies using OCTA have reported
decreased peripapillary and macular VD in glaucomatous
eyes compared to healthy eyes.19–22 OCTA has also shown
promise for monitoring glaucoma progression.20,23,24 There-
fore, OCTA may aid in identifying the pathophysiology of
glaucoma as it relates to vascular theory.
Although both measurements may play an important role
in determining vascular pathophysiology in NTG, no stud-
ies have evaluated the association between PWV and OCTA
parameters in NTG. Therefore, the present study aimed to
investigate the relationship between PWV and OCTA param-
eters and to determine which ocular parameters are associ-
ated with PWV in patients with NTG.
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METHODS
This retrospective cross-sectional study was performed in
accordance with the tenets outlined in the Declaration of
Helsinki and approved by the Institutional Review Board
of Yonsei University (4-2020-0592). The requirement for
informed consent was waived due to the retrospective nature
of the study. We reviewed the medical records of all patients
treated at Severance Hospital from January 2017 to July 2020.
A total of 109 healthy controls and 103 patients with
NTG were included in this study. All participants underwent
ophthalmologic examinations. All the examinations were
carried out as usual for glaucoma patients, or patients who
visited our hospital suspected of glaucoma. These included
slit-lamp biomicroscopy, Goldmann applanation tonome-
try, gonioscopy, dilated fundus examination, measurement
of best-corrected visual acuity (BCVA), and measurement
of axial length (AXL) (IOL Master; Carl Zeiss Meditec,
Dublin, CA, USA). Spectral-domain optical coherence tomog-
raphy (OCT) (Cirrus HD-OCT, software v11.0; Carl Zeiss
Meditec) and standard automated perimetry (Humphrey
Field Analyzer II; Carl Zeiss Meditec) were performed to
evaluate glaucomatous changes. PWV was usually measured
at health check-ups, and blood tests included hemoglobin
A1c (HbA1c), total cholesterol, triglycerides, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL)
cholesterol, estimated glomerular filtration rate (eGFR), and
uric acid. The interval between glaucoma examination and
PWV measurements did not exceed six months.
Inclusion criteria were as follows: (1) age ≥ 40 years; (2)
able to confirm open angle on medical records; (3) BCVA ≥
20/40; and (4) refractive error between +3 and –6 diopters
(D) spherical and ±3 D cylindrical. NTG was diagnosed
when the maximum untreated IOP was < 21 mm Hg on
three repeated measurements obtained at different times
on separate follow-up visits and in the presence of glau-
comatous optic discs (neuroretinal rim thinning and exca-
vation), peripapillary retinal nerve fiber layer (RNFL) defect,
and glaucomatous visual field (VF) defects. Glaucomatous
VF defects were defined if a cluster of at least three contigu-
ous points had P < 0.05 on the pattern standard devia-
tion plot where at least one of these points had P < 0.01,
or if glaucoma hemifield test was outside normal limits.25
Glaucoma severity stage was based on the Hodapp-Parrish-
Anderson criteria.26 The medical records were re-evaluated
by two glaucoma specialists (T.L. and H.Y.B.). If the two
specialists could not agree on a diagnosis of NTG, the final
decision was made by a third glaucoma specialist (S.Y.L.).
Healthy controls did not have glaucomatous optic discs or
VF defects and exhibited normal RNFL thickness, which was
within 95% of the internally set database for OCT results.
Patients with poor data quality or other ocular comor-
bidities were excluded: (1) signal strength less than
7, images with artifacts; (2) eyes with a diagnosis of
pigment dispersion glaucoma, pseudoexfoliative glaucoma,
or primary angle-closure glaucoma; (3) retinal disorder
(diabetic retinopathy, age-related macular degeneration, reti-
nal detachment, etc.); (4) history of ocular trauma or intraoc-
ular surgery; (5) history of brain disorder (brain hemorrhage,
brain infarction, brain aneurysm, brain tumor, etc.); and (6)
history of optic nerve disorder (optic neuritis, ischemic optic
neuropathy, optic coloboma, etc.).
For patients with NTG, the eye with a more severe glau-
coma status was chosen as the study eye. If patients had a
similar glaucoma severity in both eyes, the study eye was
randomly selected. For patients with healthy eyes, the study
eye was also randomly selected.
Pulse Wave Velocity
Brachial-ankle PWV (baPWV) was measured using volume-
plethysmography (VP-1000 plus; Omron HealthCare Co.
Ltd., Kyoto, Japan). Trained technicians and physicians
placed the pressure cuffs on both arms and both ankles of
the patient and performed the measurement after the patient
had rested for approximately 10 minutes in the supine posi-
tion. The travel path from body height was extrapolated, and
baPWV was computed automatically by dividing the time
difference between the pulse waves that were transmitted to
the brachial and ankle arteries by the travel path. The faster
value of the right- and left-side baPWV was used for anal-
ysis. The device also measured blood pressure (BP) at the
same time. Systolic BP (SBP) and diastolic BP (DBP) were
measured, and mean arterial pressure (MAP) was calculated
as follows: [SBP + (2 × DBP)]/3.
We set a baPWV of 1400 cm/s as the reference value since
this is what has been identified as an independent risk factor
in the Framingham score and can distinguish patients with
atherosclerotic cardiovascular disease.27,28 It is also adopted
as a reference value in the 2017 American College of Cardi-
ology/American Heart Association (ACC/AHA) Guideline for
the Prevention, Detection, Evaluation, and Management of
High Blood Pressure in Adults.29
OCTA
Under pupil dilation, OCTA (AngioPlex; Carl Zeiss Meditec)
images of the peripapillary and macular areas were obtained
using a 6 × 6 mm scan. The optical microangiography algo-
rithm analyzed the changes in the complex signal (both
intensity and phase changes contained within sequential
B-scans performed at the same position) and then gener-
ated en face microvascular images. In the 6 × 6 mm scan,
there were 350 A-scans in each B-scan along the horizon-
tal dimension, and 350 B-scans were repeated twice at each
location. The boundaries of the superficial and deep retinal
layers were determined automatically. The inner surface of
the superficial retinal layer (SRL) was defined by the inter-
nal limiting membrane. The outer surface of the SRL was
denoted by the outer border of inner plexiform layer. The
segmentation software automatically detected the bound-
aries of the retinal layers from the structural OCT cross-
sectional images by measuring the gradient of OCT signals
to create SRL en face images. With the aid of innate software
for AngioPlex OCTA, VD was defined as the total length of
perfused vasculature per unit area in a region of measure-
ment. The innate software automatically calculated the VD in
the center circle with a diameter of 6 mm. It included all the
vessels in the area, including large vessels. Thus, peripapil-
lary VD (pVD) and macular VD (mVD) were calculated. All
examinations were individually reviewed by two glaucoma
specialists (T.L. and H.W.B.), and images with artifacts or
signal strength less than 7 were excluded.
Statistical Analysis
All statistical analyses were performed using the
commercially available software SPSS (ver. 23.0; SPSS
Inc., Chicago, IL, USA). Continuous variables were
summarized as mean and standard deviation. Categorical
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variables were summarized as frequencies and percent-
ages. Demographic and clinical data between groups
were compared using independent t-tests for continuous
parameters and chi-square tests for categorical parameters.
Univariate logistic regression analysis was used to identify
the factors associated with high PWV in each group. Vari-
ables with P values less than 0.2 during the univariate step
were further included in a multivariate backward stepwise
logistic regression model. In all analyses, P values less than
0.05 were considered to indicate statistical significance.
RESULTS
In total, 109 eyes of 109 healthy controls and 103 eyes of
103 patients with NTG were enrolled. Table 1 presents the
baseline characteristics of the study population. Patients in
the NTG group were significantly older (P = 0.006) and
more frequently had hypertension (P = 0.014) than healthy
controls. SBP and MAP were significantly higher (P = 0.011,
P = 0.039, respectively), while total cholesterol and LDL
cholesterol were lower (P = 0.030, P = 0.004, respectively)
in the NTG group than in the control group. PWV was also
much faster in the NTG group than in the control group (P
= 0.026).
Patients in the NTG group exhibited reduced pVD and
mVD when compared to healthy controls (P < 0.001, P =
0.002, respectively). Average RNFL thickness and average
ganglion cell–inner plexiform layer (GCIPL) thickness were
thinner in the NTG group than in the control group (all P
< 0.001). IOP was slightly lower (P = 0.041), and spherical
equivalents (SE) were more myopic (P = 0.022) in the NTG
group than in the control group, although the difference was
relatively small. In the NTG group, the majority of patients
(86 eyes, 83.5%) were in the early stage of glaucoma, with
a mean deviation better than –6 dB in the VF test. Figure
1 and Figure 2 depict representative cases in the healthy
control and NTG groups, respectively.
Table 2 shows demographic characteristics for the low
PWV group (PWV < 1400 cm/s) and high PWV group (PWV
≥ 1400 cm/s) in healthy controls. The high PWV group was
significantly older (P < 0.001), more hyperopic (P = 0.008),
and more frequently had hypertension (HTN) (P < 0.001)
than the low PWV group.
A univariate logistic regression analysis revealed that high
PWV was significantly associated with age, SBP, DBP, MAP,
and SE (all P < 0.05). Variables with P values less than 0.2
were further enrolled in a multivariate model. Since SBP,
DBP, and MAP have multicollinearity, MAP was chosen for
the multivariate model. A multivariate backward stepwise
logistic regression analysis revealed that age (odds ratio
(OR) = 1.151, 95% confidence interval (CI) = 1.072-1.237,
P < 0.001), MAP (OR = 1.117, 95% CI = 1.060–1.178),
and LDL cholesterol (OR = 0.987, 95% CI = 0.974–1.000,
P = 0.046) were significantly associated with high PWV in
healthy controls (Table 3).
TABLE 1. Demographic Characteristics in the Healthy Control and NTG Groups
Healthy (n = 109) NTG (n = 103) P Value
Systemic parameters
Age (years) 58.1 ± 9.1 61.6 ± 9.3 0.006
Male (%) 57 (52.3) 55 (53.4) 0.872
Body mass index (kg/m2) 24.0 ± 3.5 24.0 ± 3.0 0.210
Pulse wave velocity (cm/s) 1436.6 ± 275.7 1537.8 ± 369.0 0.025
Hypertension (%) 31 (28.4) 46 (44.7) 0.014
Systolic BP (mmHg) 122.2 ± 15.3 127.9 ± 17.1 0.011
Diastolic BP (mmHg) 75.1 ± 10.7 77.3 ± 10.2 0.131
Mean arterial pressure (mmHg) 90.8 ± 11.8 94.2 ± 11.8 0.039
Diabetes mellitus (%) 22 (20.2) 22 (21.4) 0.833
HbA1c (%) 5.9 ± 1.2 6.0 ± 1.2 0.550
Dyslipidemia (%) 33 (30.3) 37 (35.9) 0.382
Total cholesterol (mg/dL) 189.2 ± 40.5 176.6 ± 43.7 0.030
Triglycerides (mg/dL) 103.4 ± 68.7 127.5 ± 84.2 0.024
HDL cholesterol (mg/dL) 53.9 ± 12.8 50.6 ± 11.8 0.055
LDL cholesterol (mg/dL) 116.3 ± 38.3 101.2 ± 38.1 0.004
Chronic kidney disease (%) 3 (2.8) 9 (8.7) 0.059
eGFR (ml/min) 92.2 ± 14.0 86.9 ± 18.5 0.019
Uric acid 5.3 ± 1.4 5.5 ± 1.6 0.363
Ocular parameters
Intraocular pressure (mmHg) 14.0 ± 2.9 13.3 ± 2.0 0.041
Axial length (mm) 24.2 ± 1.2 24.3 ± 1.4 0.340
Spherical equivalent (D) −0.6 ± 1.9 −1.4 ± 2.8 0.022
Average RNFL thickness (μm) 94.1 ± 8.9 77.4 ± 12.3 <0.001
Average GCIPL thickness (μm) 82.0 ± 6.0 71.8 ± 8.3 <0.001
Peripapillary VD (mm−1) 17.2 ± 1.0 16.2 ± 1.6 <0.001
Macular VD (mm−1) 16.7 ± 1.7 15.9 ± 1.9 0.002
Visual field mean deviation (dB) −3.7 ± 3.6
Glaucoma severity
Early 86 (83.5%)
Moderate to severe 17 (16.5%)
NTG: normal-tension glaucoma; BP: blood pressure; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein;
eGFR: estimated glomerular filtration rate; RNFL: retinal nerve fiber layer; GCIPL: ganglion cell–inner plexiform layer; VD: vessel density.
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FIGURE 1. A representative case in the healthy control group. All examination results were normal. (a) Color and red-free fundus photog-
raphy; (b) RNFL and GCIPL thickness on OCT; (c) VF; (d) Peripapillary VD and macular VD on OCTA; (e) baPWV. RNFL: retinal nerve fiber
layer; GCIPL: ganglion cell–inner plexiform layer; OCT: optical coherence tomography; VF: visual field; VD: vessel density; OCTA: optical
coherence tomography angiography; baPWV: brachial-ankle pulse wave velocity.
FIGURE 2. A representative case in the NTG group. (a) Color and red-free fundus photography; (b) OCT showed RNFL and GCIPL defects
in the inferior region; (c) Paracentral VF defect in the superior hemifield; (d) Peripapillary and macular VD were reduced on OCTA; (e)
baPWV was increased to 1669 cm/s (right) and 1779 cm/s (left). RNFL: retinal nerve fiber layer; GCIPL: ganglion cell–inner plexiform
layer; OCT: optical coherence tomography; VF: visual field; VD: vessel density; OCTA: optical coherence tomography angiography; baPWV:
brachial-ankle pulse wave velocity.
Table 4 shows demographic characteristics for the low
PWV group and high PWV group in patients with NTG. The
high PWV group was significantly older (P < 0.001) and
more frequently had HTN (P = 0.002), diabetes mellitus
(DM) (P = 0.009), and chronic kidney disease (P = 0.007)
than the low PWV group. SBP, DBP, MAP (all P < 0.001),
and HbA1c (P = 0.022) were significantly higher, while total
cholesterol (P= 0.030) and LDL cholesterol (P= 0.017) were
lower in the high PWV group than in the low PWV group. In
addition, the high PWV group had significantly shorter AXL
(P = 0.008), more hyperopic SE (P = 0.010) and lower pVD
(P = 0.036) and mVD (P < 0.001) than the low PWV group.
A univariate logistic regression analysis revealed that high
PWV was significantly associated with age, SBP, DBP, MAP,
HbA1c, total cholesterol, LDL cholesterol, eGFR, AXL, SE,
pVD, and mVD (all P < 0.05). A multivariate backward step-
wise logistic regression analysis revealed that age (OR =
1.228, 95% CI = 1.113–1.356, P < 0.001), MAP (OR = 1.221,
95% CI = 1.112–1.341, P < 0.001), and mVD (OR = 0.655,
95% CI = 0.445–0.964, P = 0.032) were significantly associ-
ated with high PWV (Table 5).
DISCUSSION
To our knowledge, this is the first study to evaluate the rela-
tionship between PWV and retinal VD in NTG. Our find-
ings confirmed that high PWV is associated with decreased
mVD in patients with NTG, indicating that systemic arte-
rial stiffness may play a role in the vascular pathophysiol-
ogy of NTG. The vascular theory is thought to be a main
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TABLE 2. Demographic Characteristics of the Low PWV and High PWV Groups in Healthy Controls
Low PWV (n = 44) High PWV (n = 59)
(PWV < 1400 cm/s) (PWV ≥ 1400 cm/s) P Value
Systemic parameters
Age (years) 54.6 ± 8.0 62.5 ± 8.4 <0.001
Male (%) 34 23 0.417
Body mass index (kg/m2) 24.0 ± 3.8 24.0 ± 3.2 0.998
Pulse wave velocity (cm/s) 1247.6 ± 129.6 1676.7 ± 219.1 <0.001
Hypertension (%) 9 22 <0.001
Systolic BP (mmHg) 115.9 ± 12.4 130.3 ± 15.1 <0.001
Diastolic BP (mmHg) 71.7 ± 9.4 79.5 ± 10.9 <0.001
Mean arterial pressure (mmHg) 86.4 ± 9.9 96.4 ± 11.8 <0.001
Diabetes (%) 9 13 0.111
HbA1c (%) 5.7 ± 1.1 6.1 ± 1.2 0.087
Dyslipidemia (%) 17 16 0.538
Total cholesterol (mg/dL) 194.6 ± 44.2 182.4 ± 34.7 0.121
Triglycerides (mg/dL) 97.4 ± 52.5 110.9 ± 84.7 0.312
HDL cholesterol (mg/dL) 54.4 ± 12.5 53.3 ± 13.2 0.660
LDL cholesterol (mg/dL) 122.1 ± 39.7 109.1 ± 35.6 0.080
Chronic kidney disease (%) 2 1 0.705
eGFR (ml/min) 94.0 ± 14.3 90.0 ± 13.4 0.142
Uric acid (mg/dL) 5.3 ± 1.4 5.4 ± 1.3 0.785
Ocular parameters
Intraocular pressure (mmHg) 13.9 ± 2.9 14.1 ± 3.0 0.771
Axial length (mm) 24.3 ± 1.2 23.9 ± 1.1 0.065
Spherical equivalent (diopters) −1.1 ± 1.9 −0.1 ± 1.7 0.008
Average RNFL thickness (μm) 93.9 ± 8.2 94.5 ± 9.7 0.698
Average GCIPL thickness (μm) 82.3 ± 5.6 81.6 ± 6.5 0.574
Peripapillary VD (mm−1) 17.3 ± 1.1 17.1 ± 0.7 0.212
Macular VD (mm−1) 16.9 ± 1.7 16.5 ± 1.6 0.157
PWV: pulse wave velocity; BP: blood pressure; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein;
eGFR: estimated glomerular filtration rate; RNFL: retinal nerve fiber layer; GCIPL: ganglion cell–inner plexiform layer; VD: vessel density.
TABLE 3. Univariate and Multivariate Backward Stepwise Logistic Regression Analysis for High PWV (PWV ≥ 1400 cm/s) in the Healthy
Control Group
Univariate Multivariate
Odds Ratio 95% CI P Value Odds Ratio 95% CI P Value
Age, years 1.126 1.064–1.193 <0.001 1.151 1.072–1.237 <0.001
Sex, male 1.369 0.641–2.924 0.418
Body mass index (kg/m2) 1.000 0.897–1.114 0.998
Systolic BP (mmHg) 1.083 1.044–1.123 <0.001
Diastolic BP (mmHg) 1.086 1.036–1.137 0.001
Mean arterial pressure (mmHg) 1.098 1.048–1.151 <0.001 1.117 1.060–1.178 <0.001
HbA1c (%) 1.358 0.936–1.971 0.107
Total cholesterol (mg/dL) 0.992 0.983–1.002 0.123
Triglycerides (mg/dL) 1.003 0.997–1.009 0.317
HDL cholesterol (mg/dL) 0.993 0.964–1.023 0.657
LDL cholesterol (mg/dL) 0.991 0.981–1.001 0.083 0.987 0.974–1.000 0.046
eGFR (ml/min) 0.979 0.952–1.007 0.146
Uric acid (mg/dL) 1.040 0.787–1.376 0.782
Intraocular pressure (mmHg) 1.020 0.895–1.161 0.768
Axial length (mm) 0.728 0.517–1.025 0.069
Spherical equivalent (diopters) 1.358 1.072–1.721 0.011
Average RNFL thickness (μm) 1.009 0.966–1.053 0.695
Average GCIPL thickness (μm) 0.982 0.921–1.046 0.570
Peripapillary VD (mm−1) 0.782 0.522–1.171 0.232
Macular VD (mm−1) 0.850 0.678–1.065 0.158
Hosmer-Lemeshow P value: 0.068
Nagelkerke R2 = 0.492
Variables with P values less than 0.2 during the univariate step were further enrolled in a backward stepwise logistic regression model.
PWV: pulse wave velocity; CI: confidence interval; BP: blood pressure; Hb: hemoglobin; HDL: high-density lipoprotein; LDL: low-density
lipoprotein; eGFR: estimated glomerular filtration rate; RNFL: retinal nerve fiber layer; GCIPL: ganglion cell–inner plexiform layer; VD: vessel
density.
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TABLE 4. Demographic Characteristics of the Low PWV and High PWV Groups in the NTG Group
Low PWV (n = 44) High PWV (n = 59)
(PWV < 1400 cm/s) (PWV ≥ 1400 cm/s) P Value
Systemic parameters
Age (years) 56.3 ± 7.2 65.6 ± 8.7 <0.001
Male (%) 28 27 0.072
Body mass index (kg/m2) 24.3 ± 3.1 23.6 ± 2.8 0.232
Pulse wave velocity (cm/s) 1242.0 ± 90.4 1758.3 ± 342.8 <0.001
Hypertension (%) 12 34 0.002
Systolic BP (mmHg) 116.7 ± 11.6 136.3 ± 15.7 <0.001
Diastolic BP (mmHg) 72.6 ± 8.3 80.7 ± 10.2 <0.001
Mean arterial pressure (mmHg) 87.3 ± 9.0 99.3 ± 11.0 <0.001
Diabetes (%) 4 18 0.009
HbA1c (%) 5.7 ± 0.8 6.2 ± 1.4 0.022
Dyslipidemia (%) 14 2 0.453
Total cholesterol (mg/dL) 187.4 ± 37.9 168.6 ± 46.2 0.030
Triglycerides (mg/dL) 129.2 ± 91.2 126.3 ± 79.4 0.860
HDL cholesterol (mg/dL) 51.9 ± 10.6 49.7 ± 12.7 0.356
LDL cholesterol (mg/dL) 111.5 ± 35.4 93.5 ± 38.5 0.017
Chronic kidney disease (%) 0 9 0.007
eGFR (ml/min) 94.7 ± 14.0 81.1 ± 19.4 <0.001
Uric acid 5.8 ± 1.6 5.3 ± 1.5 0.121
Ocular parameters
Intraocular pressure (mmHg) 12.9 ± 2.0 13.6 ± 1.9 0.057
Axial length (mm) 24.8 ± 1.5 24.0 ± 1.3 0.008
Spherical equivalent (D) −2.2 ± 3.0 −0.8 ± 2.5 0.010
Average RNFL thickness (μm) 78.7 ± 12.2 76.4 ± 12.4 0.359
Average GCIPL thickness (μm) 72.7 ± 8.1 71.1 ± 8.4 0.343
Peripapillary VD (mm−1) 16.6 ± 1.6 15.9 ± 1.5 0.036
Macular VD (mm−1) 16.8 ± 1.7 15.3 ± 1.8 <0.001
Visual field mean deviation (dB) −4.0 ± 4.7 −3.4 ± 2.4 0.436
PWV: pulse wave velocity; NTG: normal-tension glaucoma; BP: blood pressure; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein;
LDL: low-density lipoprotein; eGFR: estimated glomerular filtration rate; RNFL: retinal nerve fiber layer; GCIPL: ganglion cell–inner plexiform
layer; VD: vessel density.
factor influencing NTG,30,31 given its relevance to systemic
vascular dysregulation, including vascular and endothe-
lial diseases,32 vasospasm syndrome,33 and migraine.34,35
PWV reflects systemic arterial stiffness, and OCTA evalu-
ates the microvascular status of the eye, which is an end
organ. The relevance of these two parameters supports
the vascular theory of NTG and suggests the impor-
tance of systemic vessel status evaluations in patients with
NTG.
Although several studies have investigated the relation-
ship between PWV and glaucoma, they have yielded conflict-
ing results. The Rotterdam Eye Study15 first showed that
participants with an increased carotid-femoral PWV (cfPWV)
and especially those with a low carotid distensibility coef-
ficient, both indicative of high arterial stiffness, had a
higher prevalence of primary open-angle glaucoma (POAG),
although the results were not statistically significant. In other
studies regarding the relationship between cfPWV and glau-
coma, cfPWV exhibited a stepwise increase from healthy
controls to patients with POAG and those with pseudoexfo-
liative glaucoma,13 and such increases in cfPWV were associ-
ated with pseudoexfoliative glaucoma.17 Other studies eval-
uated the relationship between baPWV and glaucoma. One
study reported that baPWV was positively associated with
glaucoma and NTG in particular, while other studies failed to
identify a significant difference in baPWV between patients
with NTG and healthy controls.12,14 These diverse results
may be due to the different glaucoma subgroups and differ-
ent modalities used to measure PWV.
The two most frequently applied measurements of PWV
are cfPWV and baPWV. We used baPWV due to its simplicity
and noninvasiveness. baPWV is measured simply by wrap-
ping pressure cuffs around the four extremities without
taking off clothes and is an independent marker of future
cardiovascular events.6,7 baPWV may be applicable even in
those with a low risk of cardiovascular disease (CVD),6 while
cfPWV is thought to be applicable in patients with a high risk
of CVD.36 Therefore, baPWV measurements are included in
routine health check-up programs in South Korea. Consid-
ering the relationship between these measurements and
other ocular disorders such as diabetic retinopathy,8,9 reti-
nal vein occlusion,10 and age-related macular degenera-
tion,11 the result of our study—which identified a correla-
tion between PWV and mVD measured by OCTA in patients
with NTG—suggests the necessity of ophthalmologic exam-
ination for patients who have high PWV. Although there is a
lack of evidence now, if further research confirms that PWV
is not only related with glaucoma but also a risk factor that
increases the risk of glaucoma development or progression,
PWV will be an important test to evaluate the condition of
glaucoma patients.
It is well known that NTG is associated with systemic
vascular factors and impaired ocular blood flow.37 There-
fore, a relationship between decreased VD and increased
systemic arterial stiffness can be expected in patients with
NTG. However, the mechanism underlying the associa-
tion between high systemic arterial stiffness and decreased
mVD in NTG remains unclear. One possible explanation is
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TABLE 5. Univariate and Multivariate Backward Stepwise Logistic Regression Analysis for High PWV (PWV ≥ 1400 cm/s) in NTG Group
Univariate Multivariate
Odds Ratio 95% CI P Value Odds Ratio 95% CI P Value
Age, years 1.153 1.083–1.229 <0.001 1.228 1.113–1.356 <0.001
Sex, male 2.074 0.932–4.615 0.074
Body mass index (kg/m2) 0.921 0.805–1.054 0.233
Systolic BP (mmHg) 1.123 1.070–1.178 <0.001
Diastolic BP (mmHg) 1.099 1.045–1.155 <0.001
Mean arterial pressure (mmHg) 1.131 1.071–1.194 <0.001 1.221 1.112–1.341 <0.001
HbA1c (%) 1.611 1.003–2.589 0.049
Total cholesterol (mg/dL) 0.990 0.980–0.999 0.034
Triglycerides (mg/dL) 1.000 0.995–1.004 0.859
HDL cholesterol (mg/dL) 0.984 0.952–1.018 0.353
LDL cholesterol (mg/dL) 0.987 0.976–0.998 0.020
eGFR (ml/min) 0.948 0.919–0.978 0.001
Uric acid (mg/dL) 0.815 0.628–1.058 0.124
Intraocular pressure (mmHg) 1.220 0.991-1.503 0.061
Axial length (mm) 0.675 0.498–0.915 0.011
Spherical equivalent (diopters) 1.214 1.041–1.417 0.014
Average RNFL thickness (μm) 0.985 0.954–1.017 0.356
Average GCIPL thickness (μm) 0.977 0.931–1.025 0.341
Peripapillary VD (mm−1) 0.750 0.570–0.988 0.041
Macular VD (mm−1) 0.605 0.461–0.796 <0.001 0.655 0.445–0.964 0.032
Hosmer-Lemeshow P value: 0.595
Nagelkerke R2 = 0.672
Variables with P values less than 0.2 during the univariate step were further enrolled in a backward stepwise logistic regression model.
PWV: pulse wave velocity; NTG: normal-tension glaucoma; BP: blood pressure; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein;
LDL: low-density lipoprotein; eGFR: estimated glomerular filtration rate; RNFL: retinal nerve fiber layer; GCIPL: ganglion cell–inner plexiform
layer; VD: vessel density.
that, although baPWV reflects the stiffness of medium- to
large-sized arteries, excessive pressure pulsatility may affect
microvascular remodeling and impair the regulation of local
blood flow, which can lead to diffuse microscopic tissue
damage.38 This notion is supported by another study, which
demonstrated that increased aortic stiffness is inversely
correlated with retinal arterial lumen diameter and increased
microvascular resistance.39 Moreover, one study reported
that untreated NTG eyes had stiffer retinal vessels and that
vessel rigidity correlates with the level of glaucomatous
damage.40 Further studies are required to identify the mech-
anism underlying the relationship between systemic arterial
stiffness and retinal vessel damage.
In this study, baPWV was significantly associated with
mVD but not with pVD. One possible explanation is that
there is an NTG subtype in which glaucomatous changes
first occur in the macular GCIPL rather than the peripapillary
RNFL.41,42 Since the SRL of OCTA is composed of the area
from the inner limiting membrane to the inner plexiform
layer and our study group mainly consisted of patients with
early-stage NTG, mVD may have been affected and impaired
earlier. Further studies are required to determine the associ-
ation between PWV and OCTA at different glaucoma stages
and in different subtypes of glaucoma along with the pattern
of VF progression.
Our findings also revealed that high PWV is associated
with age and MAP in both groups. Age is a strong predic-
tor of PWV,43 and PWV is well known to be dependent on
blood pressure at the time of measurement.44–46 Age and
BP are also among the important factors to consider when
evaluating retinal VD.47–49 Therefore, age and BP should
be considered when interpreting the relationship between
PWV and mVD. Moreover, PWV has been associated with
DM,50,51 abnormal lipid metabolism,52,53 smoking,54 elevated
uric acid levels,55 high body mass index,56 and chronic
kidney disease.57,58 Although we included all the possible
systemic factors influencing PWV as covariates, mVD was
still significantly associated with PWV in patients with NTG
in the multivariate logistic regression analysis.
There are some limitations in this study. First, this
was a retrospective cross-sectional study, and the associa-
tion discovered here may not imply a causal relationship.
Cautions are needed when interpreting the results. Further
study is needed for the mechanism underlying the rela-
tionship between PWV and mVD in NTG. Second, we only
included data with good image quality, as signal strength is
an important factor when analyzing OCTA images. Thus, it is
possible that selection bias occurred. However, these condi-
tions would have contributed to increasing the reliability of
our study results. Third, the sample in this study comprised
mostly patients with early-stage NTG (86 eyes, 83.5%). This
must be considered when using the results of our study to
inform clinical practice, as the relationship may differ in
patients with more advanced NTG or other types of glau-
coma, such as POAG. Studies comparing POAG with NTG
may aid in clarifying the significance of PWV in glaucoma.
Lastly, because of its retrospective study design, we were
unable to account for all the factors that affect the measure-
ment of PWV and OCTA. Further studies that consider all
possible factors are required.
In conclusion, our study demonstrates that high PWV is
associated with decreased mVD in patients with NTG, indi-
cating that systemic arterial stiffness might be involved in
the pathogenesis of NTG. These results further indicate that
clinical diagnosis and treatment of NTG may require consid-
eration of systemic arterial stiffness, which can be confirmed
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by measuring PWV. In addition, further research regarding
the role of systemic arterial stiffness in the pathogenesis of
NTG is needed.
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